Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP1 | P22413 | 2/20 | 0.53 |
| ▸ | TNF | P01375 | 4/20 | 0.49 |
| ▸ | HDAC3 | O15379 | 8/20 | 0.49 |
| ▸ | HDAC4 | P56524 | 8/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 8/20 | 0.49 |
| ▸ | HDAC7 | Q8WUI4 | 8/20 | 0.49 |
| ▸ | HDAC2 | Q92769 | 8/20 | 0.49 |
| ▸ | HDAC10 | Q969S8 | 8/20 | 0.49 |
| ▸ | HDAC11 | Q96DB2 | 8/20 | 0.49 |
| ▸ | HDAC8 | Q9BY41 | 8/20 | 0.49 |
| ▸ | HDAC6 | Q9UBN7 | 8/20 | 0.49 |
| ▸ | HDAC9 | Q9UKV0 | 8/20 | 0.49 |
| ▸ | HDAC5 | Q9UQL6 | 8/20 | 0.49 |
| ▸ | ERBB2 | P04626 | 4/20 | 0.49 |
| ▸ | EGFR | P00533 | 3/20 | 0.49 |
| ▸ | KDR | P35968 | 8/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4337599 | 1.00 | ENPP1 (0.53) | ENPP1TNFHDAC3HDAC4HDAC1 | |
| SCHEMBL4329011 | 0.93 | ENPP1 (0.63) | ENPP1TNFHDAC3HDAC4HDAC1 | |
| SCHEMBL641754 | 0.93 | ENPP1 (0.63) | ENPP1TNFHDAC3HDAC4HDAC1 | |
| SCHEMBL15953550 | 0.88 | ENPP1 (0.66) | ENPP1TNFHDAC3HDAC4HDAC1 | |
| SCHEMBL17836941 | 0.88 | ENPP1 (0.56) | ENPP1HDAC3HDAC1HDAC6EGFR | |
| SCHEMBL12518967 | 0.87 | ENPP1 (0.46) | ENPP1TNFHDAC3HDAC4HDAC1 | |
| SCHEMBL3517589 | 0.86 | HDAC3 (0.48) | ENPP1TNFHDAC3HDAC4HDAC1 | |
| SCHEMBL3518656 | 0.86 | HDAC3 (0.48) | ENPP1TNFHDAC3HDAC4HDAC1 | |
| SCHEMBL163465 | 0.81 | ENPP1 (0.71) | ENPP1EGFRKDR | |
| SCHEMBL642824 | 0.80 | TNF (0.50) | TNFHDAC3HDAC4HDAC1HDAC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150284340-A1 | QUINAZOLINE BASED EGFR INHIBITORS CONTAINING A ZINC BINDING MOIETY | CURIS INC (US) | 2015-10-08 | — | — | US | disclosed |
| US-20150274678-A1 | QUINAZOLINE BASED EGFR INHIBITORS CONTAINING A ZINC BINDING MOIETY | CURIS INC (US) | 2015-10-01 | — | — | US | disclosed |
| US-9024024-B2 | Quinazoline based EGFR inhibitors containing a zinc binding moiety | CURIS, INC. (US) | 2015-05-05 | — | — | US | disclosed |
| US-8975401-B2 | Quinazoline based EGFR inhibitors containing a zinc binding moiety | CURIS, INC. (US) | 2015-03-10 | — | — | US | disclosed |
| EP-2190287-B1 | TARTRATE SALTS OR COMPLEXES OF QUINAZOLINE BASED EGFR INHIBITORS CONTAINING A ZINC BINDING MOIETY | CURIS INC (US) | 2014-10-29 | — | — | EP | disclosed |
| US-8846912-B2 | Tartrate salts of quinazoline based EGFR inhibitors containing a zinc binding moiety | CURIS, INC. (US) | 2014-09-30 | — | — | US | disclosed |
| US-20140221403-A1 | QUINAZOLINE BASED EGFR INHIBITORS CONTAINING A ZINC BINDING MOIETY | CURIS, INC. (US) | 2014-08-07 | — | — | US | disclosed |
| US-20140155606-A1 | QUINAZOLINE BASED EGFR INHIBITORS CONTAINING A ZINC BINDING MOIETY | CURIS, INC. (US) | 2014-06-05 | — | — | US | disclosed |
| US-20130338167-A1 | TARTRATE SALTS OF QUINAZOLINE BASED EGFR INHIBITORS CONTAINING A ZINC BINDING MOIETY | CURIS, INC. (US) | 2013-12-19 | — | — | US | disclosed |
| US-8604044-B2 | Quinazoline based EGFR inhibitors containing a zinc binding moiety | CURIS, INC. (US) | 2013-12-10 | — | — | US | disclosed |
| EP-2061772-A2 | MULTI-FUNCTIONAL SMALL MOLECULES AS ANTI-PROLIFERATIVE AGENTS | Curis, Inc. (US) | 2009-05-27 | — | — | EP | disclosed |
| US-20090111772-A1 | FORMULATION OF QUINAZOLINE BASED EGFR INHIBITORS CONTAINING A ZINC BINDING MOIETY | CURIS, INC. | 2009-04-30 | — | — | US | disclosed |
| WO-2009035718-A1 | TARTRATE SALTS OR COMPLEXES OF QUINAZOLINE BASED EGFR INHIBITORS CONTAINING A ZINC BINDING MOIETY | CURIS, INC. (US) | 2009-03-19 | — | — | WO | disclosed |
| US-20090076022-A1 | epidermal growth factor receptor tyrosine kinase (EGFR-TK) and histone deacetylase inhibitors such as 2-(4-(3-Chloro-4-fluorophenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyacetamide, used as anticarcinogenic agents | CURIS, INC. | 2009-03-19 | — | — | US | disclosed |
| US-20080221132-A1 | Multi-Functional Small Molecules as Anti-Proliferative Agents | CURIS, INC. | 2008-09-11 | — | — | US | disclosed |
| US-20080194578-A1 | inhibitors of epidermal growth factor receptor tyrosine kinase and histone deacetylase; 2-(4-(3-Chloro-4-fluorophenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyacetamide; anticarcinogenic agent | CURIS, INC. | 2008-08-14 | — | — | US | disclosed |
| WO-2008033747-A9 | MULTI-FUNCTIONAL SMALL MOLECULES AS ANTI-PROLIFERATIVE AGENTS | CURIS INC (MA) | 2008-07-24 | — | — | WO | disclosed |
| US-20080139590-A1 | QUINAZOLINE BASED EGFR INHIBITORS CONTAINING A ZINC BINDING MOIETY | CURIS, INC. | 2008-06-12 | — | — | US | disclosed |
| WO-2008033749-A2 | QUINAZOLINE BASED EGFR INHIBITORS CONTAINING A ZINC BINDING MOIETY | CURIS, INC. (US) | 2008-03-20 | — | — | WO | disclosed |
| WO-2008033747-A2 | MULTI-FUNCTIONAL SMALL MOLECULES AS ANTI-PROLIFERATIVE AGENTS | CURIS, INC. (US) | 2008-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090076022-A1 | epidermal growth factor receptor tyrosine kinase (EGFR-TK) and histone deacetylase inhibitors such as 2-(4-(3-Chloro-4-fluorophenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyacetamide, used as anticarcinogenic agents | EGFR, HDAC1, HDAC8 | ENPP1 2467/4885TNF 3028/4885HDAC3 11/4885 |
| US-20080221132-A1 | Multi-Functional Small Molecules as Anti-Proliferative Agents | HDAC1, HDAC6, HDAC5 | ENPP1 1158/4885TNF 3845/4885HDAC3 7/4885 |
| US-20140221403-A1 | QUINAZOLINE BASED EGFR INHIBITORS CONTAINING A ZINC BINDING MOIETY | EGFR, HDAC5, ERBB4 | ENPP1 2168/4885TNF 4568/4885HDAC3 17/4885 |
| US-20080194578-A1 | inhibitors of epidermal growth factor receptor tyrosine kinase and histone deacetylase; 2-(4-(3-Chloro-4-fluorophenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyacetamide; anticarcinogenic agent | HDAC1, HDAC8, EGFR | ENPP1 2950/4885TNF 4146/4885HDAC3 12/4885 |
| US-20140155606-A1 | QUINAZOLINE BASED EGFR INHIBITORS CONTAINING A ZINC BINDING MOIETY | EGFR, HDAC1, HDAC5 | ENPP1 1944/4885TNF 4544/4885HDAC3 19/4885 |
| US-20090111772-A1 | FORMULATION OF QUINAZOLINE BASED EGFR INHIBITORS CONTAINING A ZINC BINDING MOIETY | HDAC6, HDAC5, HDAC1 | ENPP1 3380/4885TNF 3801/4885HDAC3 12/4885 |
| US-20080139590-A1 | QUINAZOLINE BASED EGFR INHIBITORS CONTAINING A ZINC BINDING MOIETY | EGFR, HDAC1, HDAC6 | ENPP1 2641/4885TNF 4467/4885HDAC3 15/4885 |
| US-20150274678-A1 | QUINAZOLINE BASED EGFR INHIBITORS CONTAINING A ZINC BINDING MOIETY | EGFR, HDAC1, HDAC5 | ENPP1 1944/4885TNF 4544/4885HDAC3 19/4885 |
| US-20130338167-A1 | TARTRATE SALTS OF QUINAZOLINE BASED EGFR INHIBITORS CONTAINING A ZINC BINDING MOIETY | EGFR, HDAC1, HDAC5 | ENPP1 1795/4885TNF 3160/4885HDAC3 19/4885 |
| US-20150284340-A1 | QUINAZOLINE BASED EGFR INHIBITORS CONTAINING A ZINC BINDING MOIETY | EGFR, ERBB4, HDAC5 | ENPP1 2139/4885TNF 4579/4885HDAC3 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.